Table 1.
Demographics, baseline characteristics and routine laboratory values of the control, DAPT, VKA+P2Y12i and DOAC+P2Y12i groups.
| Mean (st. dev.)Median [IQR] | Control | DAPT | VKA + P2Y12i | DOAC + P2Y12i | p-value: control vs | p-value: |
|---|---|---|---|---|---|---|
| n (%) | n = 95 | n = 323 | n = 69 | n = 48 | post-PCI patients | medication groups |
| Patient characteristics | ||||||
| Age (years) | 57 [47–67] | 76 [69–81] | 78 [72–80] | 75 [71–80.75] | 0.000 | 0.552 |
| Gender (man) | 53 (55.8) | 165 (51.1) | 50 (72.5) | 32 (66.7) | 0.951 | 0.002 |
| BMIΦ | 26.0 [24.1–28.4] | 26.6 [24.1–30.0] | 27.6 [24.7–30.3] | 26.9 [23.8–30.0] | 0.065 | 0.758 |
| Smoking (yes)Φ | 22 (23.2) | 45 (14.0) | 7 (10.3) | 7 (14.6) | 0.018 | 0.697 |
| Diabetes (yes) | 5 (5.3) | 120 (37.2) | 23 (33.3) | 15 (31.3) | 0.000 | 0.648 |
| Hypertension (yes) | ND | 274 (84.8) | 58 (84.1) | 41 (85.4) | 0.978 | |
| Previous stroke (CVA and/or TIA)Φ | ND | 80 (24.8) | 22 (31.9) | 15 (31.3) | 0.364 | |
| Previous PCI | ND | 121 (37.5) | 26 (37.7) | 20 (41.7) | 0.854 | |
| Atrial fibrillation in medical history | ND | 7 (2.2) | 52 (75.4) | 45 (93.8) | 0.000 | |
| Laboratory values | ||||||
| Platelets (10∧9/L) | 259 [226–299] | 252 [214–296] | 245 [195–303] | 248.0 [212.75–311.5] | 0.286 | 0.542 |
| Leukocytes (10∧9/L) | 6.9 [5.6–8.1] | 7.6 [6.4–9.3] | 7.3 [6.7–8.6] | 7.50 [6.3–8.4] | 0.000 | 0.595 |
| Hematocrit (L/L) | 0.43 [0.41–0.45] | 0.40 [0.37–0.43] | 0.41 [0.37–0.44] | 0.41 [0.38–0.44] | 0.000 | 0.426 |
| Hemoglobin (mmol/L) | 9.0 (0.8) | 8.2 (1.0) | 8.3 (1.1) | 8.2 (1.1) | 0.000 | 0.737 |
| PT (s)Φ | 10.3 [10.1–10.5] | 10.6 [10.3–11.0] | 25.5 [21.4–32.0] | 12.7 [11.4–14.4] | 0.000 | 0.000 |
| aPTT (s)Φ | 26 (25–27) | 26.0 (25–27) | 36 (34–38) | 33.0 [29–36.75] | 0.000 | 0.000 |
| Fibrinogen (g/L)Φ | 3.2 [2.8–3.6] | 3.7 [3.1–4.2] | 3.8 [3.3–4.2] | 3.5 [3.0–4.0] | 0.000 | 0.453 |
| P2Y12 inhibitor | ||||||
| Clopidogrel | 218 (67.5) | 68 (98.6) | 43 (89.6) | 0.000 | ||
| Prasugrel | 53 (16.4) | 1 (1.4) | 1 (2.1) | |||
| Ticagrelor | 52 (16.1) | 0 (0) | 4 (8.3) | |||
| Other antithrombotic medication | ||||||
| Acenocoumarol | 62 (89.9) | |||||
| Fenprocoumon | 7 (10.1) | |||||
| Rivaroxaban | 27 (56.3) | |||||
| Dabigatran | 8 (16.7) | |||||
| Apixaban | 12 (25.0) | |||||
| Edoxaban | 1 (2.1) | |||||
| Index PCI | ||||||
| Acute | 219 (67.8) | 34 (49.3) | 31 (64.6) | 0.014 | ||
| Elective | 104 (32.2) | 35 (50.7) | 17 (35.4) | |||
| Days between ROTEM and PCI | 46 (36–56) | 47 (36–60) | 44 [37.25–53.75] | 0.824 | ||
Patient characteristics and laboratory values as presented at the outpatient department of vascular medicine one month post-PCI visit (T1; DAPT, VKA + P2Y12i, DOAC + P2Y12i groups) and the post-operative study visit (control group). PCI, percutaneous coronary intervention; BMI, body mass index; SD, standard deviation; IQR, interquartile range; PT, prothrombin time; aPTT, activated partial thromboplastin time; ND, not determined. Φ Data are missing for BMI (DAPT n = 6), smoking (DAPT n = 2, VKA+P2Y12i n = 1), previous stroke (CVA and/or TIA) (DAPT n = 1), PT/aPTT/Fibrinogen (control n = 1, DAPT n = 2).